Please login to the form below

Not currently logged in
Email:
Password:

S-A enters research deal with Stanford

Sanofi-aventis has entered into a research collaboration with Stanford University that is aimed at early-stage science

Sanofi-aventis (S-A) has entered into a research collaboration with Stanford University that is aimed at early-stage science.

The multi-year partnership allows the company to work with Stanford's Bio-X interdisciplinary life sciences research programme, which "supports, organises, and facilitates interdisciplinary, collaborative and innovative research projects in the early phases of development." The partners will work together on up to five projects a year, funded by a Joint Steering Committee.

Other elements of the collaboration include the opportunity for S-A to host postdoctoral fellows at the company and for company researchers to be invited by Stanford faculty to be visiting scholars and to pursue research collaborations at the university.

Each year, S-A will fund a research forum to allow company researchers and Stanford scientists to come together to share knowledge and ideas, as well as to discuss the projects under development.

Bio-X is a joint project of Stanford's Schools of Humanities and Sciences, Engineering, Earth Sciences and Medicine that was formed in 1998 to promote interdisciplinary research in the biosciences.

The programme has 450 affiliated faculty from 50 academic departments at the university, including biology/life sciences, engineering, computer science, clinicians/clinical research, law/ethics/mathematics/statistics and physical sciences.

"The results so far have included numerous biomedical inventions and life science discoveries that have expanded our understanding of the human body and how to treat disease," Stanford said of the programme. "But this is only the beginning: Bio-X is an experiment in progress. The achievements to date are in some sense a 'proof of principle' of even greater undertakings to come."

The collaboration follows news in January that S-A would partner with the University of California, San Francisco (UCSF), in areas including oncology, diabetes and ageing.

The company had previously announced it would partner with Harvard University on translational biomedical research in several therapeutic areas, including oncology and diabetes.

19th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics